HitGen(SH:688222)2023-11-02 01:52Group 1: Company Overview - Chengdu XianDao focuses on becoming a world-class innovative biopharmaceutical company, contributing to human health [3] - The company specializes in small molecule and nucleic acid drug discovery and optimization, leveraging four core technology platforms [3][4] - Since its establishment in 2012, Chengdu XianDao has expanded its operations globally, with subsidiaries in the UK and the US [4] Group 2: DEL Technology - Chengdu XianDao is a leader in DEL technology, with over 1.2 trillion molecules in its DEL library and more than 6,000 synthetic building blocks [4] - The company has multiple internal drug projects at various clinical stages [4] - Recent trends show a shift in customer demand from large-scale DEL libraries to smaller proprietary libraries [5] Group 3: Financial Performance - In the first three quarters of 2023, the company reported an operating cash flow of ¥65.79 million, a significant increase of ¥72.40 million compared to the same period last year [7] - The recovery in cash flow is attributed to the gradual restoration of core DEL business and commercialization of other technology platforms [7] Group 4: Drug Development Services - Chengdu XianDao offers "DEL For" and "DEL Plus" services to address key challenges in drug development [8] - The "DEL For" series focuses on specific targets to generate high-quality compounds, while "DEL Plus" integrates various applications for compound evaluation and screening [8][9] Group 5: Research and Collaboration - The company has established a partnership with the Structural Genomics Consortium (SGC) to utilize DEL technology for new target screening [11] - Chengdu XianDao has completed screening for over 200 targets across 51 categories, showcasing a diverse range of drug targets [12]